MyOme
myome.com
Molecular Diagnostics
Bioinformatics
Genomics & Genetic Testing
As featured in
Claim pageClaim
Follow
Overview
News
Technologies
Salaries
Products
People
Growth
Offices
Financials
Funding and backers
Backers
2
Foresite Capital, Sequoia Capital
Momentum
15/100
in the news
Last sign of life
this month
a posting or a news item
The story so fareach stage dated by its source: the company's releases, the press, registers, filings
Tractionpublic signals, read monthly
Web presence
top 7%
of 133.2M domains by links, Common Crawl
Backed byfrom the funds' portfolios and accelerator catalogs
Foresite Capital 
Sequoia Capital Investors in similar startupsfunds that back the companies most like this one
Similar startupsby what they do, their industry and backers
Unlock the potential of a Whole Genome Sequencing Test with Inocras. Transforming diagnosis and treatment for cancer and rare diseases.
Feanix Autopilot combines whole-genome sequencing, DairyComp, EZfeed, milk checks, feed costs, health records, and real farm performance…
Screen embryos for 400+ genetic conditions before pregnancy. Orchid's whole genome screening reads 99% of an embryo's genome — 100x more…
Genomics plc is an Oxford company founded in 2014 by statistical geneticists to turn genomic data into health insight. Its integrated risk…
Genomics England is a global leader in genomic medicine and research, focused on creating a world where everyone benefits from genomic…
Phase Genomics: Fueling Genomic Discovery. CytoTerra® Cytogenetics, ProxiMeta™ Metagenome Deconvolution, Proximo™ Genome Scaffolding.
News
MyOme and Oracle Collaborate to Advance Genomic Risk Prediction at Global Scale
/PRNewswire/ -- MyOme, Inc., a leader in clinical whole-genome analysis and polygenic risk modeling, today announced that its predictive genomic insights...
Read more
Report
Oracle Corporation and Myome, Inc. Collaborate to Advance Genomic Risk Prediction At Global Scale
Read more
Report
MyOme Debuts Zenith Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
MyOme, a leader in clinical whole-genome analysis, announced an advancement in rare disease diagnostics at the American College of Medical Genetics and Genomics (ACMG) Annual Meeting. By integrating methylation signatures (epigenetic signatures) into its
Read more
Report
MyOme Debuts Zenith Portfolio with Natera and Launches Long-Read Methylation Analysis at ACMG 2026
Read more
Report
Illumina and MyOme Strike Collaboration Deal Including Strategic Investment to Support MyOme
Illumina, Inc. (NASDAQ: ILMN) and MyOme, a leading genomics innovation and risk modeling company, today announced a collaboration and investment by Illumina into MyOme.
Read more
Report
MyOme expands rare disease test with new genome insights
MyOme expands rare disease test with new genome insights
Read more
Report
MyOme and Collective Health Partner to Expand Access to MyOme
MyOme, a leading whole-genome analysis and polygenic risk modeling (PRS) company, announced that it has joined The Partner Collective by Collective Health- a digital health partner hub that helps employers, brokers, and consultants discover and engage wit
Read more
Report
MyOme and Broad Clinical Labs to Support Southern Research Program to Bring Genetics-Driven Health Insights to Alabamians Free of Charge
/PRNewswire/ -- MyOme, Inc., a leading clinical genetics innovation company, and Broad Clinical Labs (BCL), a world expert in whole genome sequencing (WGS) are...
Read more
Report
MyOme Presents New Data: Improved 10-year Risk Prediction of Coronary Artery Disease through Polygenic Risk Scores Integrated with Clinical Factors Showcased at the American ...
Read more
Report
MyOme Presents New Data on an Integrated Polygenic Risk Score to Improve Coronary Artery Disease Prediction at the American College of Medical Genetics and Geno
Integrated polygenic risk score can more accurately identify people at high risk of developing coronary artery disease across diverse ancestries over a commonly used clinical tool.
Read more
Report
Tech stack
Technologies named in job postings at MyOme over the last 12 months, by layer, with the share of postings for each.
Technologies in use
2
Postings analysed
1
Stack modernity
85/100
Languages
Python
Practices & domains
CI/CD
Sign in to see how your skills match this stack
Sign In
Growth
Hiring Momentum
23/100
Hiring freeze
Open positions
0
0 opened / 0 closed in 30 days
Median time-to-fill
60 days
faster than 23% of the market
Hiring Dynamics
0%
Hiring Focus
The percentage next to each role is its share of the company's job openings over the last 90 days; the arrow shows the shift versus the previous period.
Backend
100% ▼